| Value | ₹4.18 Cr |
|---|
BSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,175.50
- Market cap
- ₹1,18,283 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.2×Sector 46.1×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Capacity Expansion: ₹190 Cr Investment
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.
- Value
- ₹190.0 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences presented post-hoc analysis from its EPICS-III clinical trial for Saroglitazar at ACG 2026. The drug remains under regulatory review for PBC treatment.
Other legal & regulatory announcements
All →Coromandel International Legal & Regulatory
Coromandel International received a Deputy Commissioner (Appeal) GST order-in-appeal for FY 2019-20 confirming ineligible input tax credit demand. The company will appeal before GSTAT and expects no significant financial impact.
- Value
- ₹0.18 Cr
Taurian Mps Legal & Regulatory
Taurian MPS received a SEBI adjudication order imposing penalties of Rs.5 lakh on the company, Rs.5 lakh on promoters jointly, and Rs.8 lakh on the merchant banker. The penalties relate to IPO offer document disclosure deficiencies.
- Value
- ₹0.05 Cr
Coromandel International Legal & Regulatory
Coromandel International received a GST Order-in-Appeal confirming a ₹1.79 Crore tax demand. Including interest and penalty, the total is ₹4.05 Crore; the company will appeal.
- Value
- ₹4.05 Cr
Shreeji Global FMCG Legal & Regulatory
Shreeji Global FMCG received a customs Order-in-Original demanding about ₹42.47 Crore in duty, penalties and redemption fines. The company plans to appeal before CESTAT.
- Value
- ₹42.47 Cr
HD Fire Protect Legal & Regulatory
HD Fire Protect received an MPCB refusal of Consent to Operate for its Jalgaon expansion sheds. Existing manufacturing operations continue, with no material impact anticipated.
Krishna Institute of Medical Sciences Legal & Regulatory
KIMS discloses a pending suit over its Chennai hospital land lease, naming it defendant. Supreme Court dismissed its SLP; no injunction halts the project.